FDA Planning More Inspections Of Gene Therapy Trials During IND Phase

FDA plans to step up inspections of gene therapy trials while they are in the IND phase, FDA Office of Therapeutics Research & Review Director Jay Siegel, MD, told the Senate Health/Public Health Subcommittee during a Feb. 2 hearing on gene therapy.